WO2019079402A2 - Systèmes d'administration améliorés pour des fractions comprenant des combinaisons améliorées de cbd, formulations et chimères - Google Patents

Systèmes d'administration améliorés pour des fractions comprenant des combinaisons améliorées de cbd, formulations et chimères Download PDF

Info

Publication number
WO2019079402A2
WO2019079402A2 PCT/US2018/056224 US2018056224W WO2019079402A2 WO 2019079402 A2 WO2019079402 A2 WO 2019079402A2 US 2018056224 W US2018056224 W US 2018056224W WO 2019079402 A2 WO2019079402 A2 WO 2019079402A2
Authority
WO
WIPO (PCT)
Prior art keywords
patch
cbd
thc
adhesive
vol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/056224
Other languages
English (en)
Other versions
WO2019079402A3 (fr
Inventor
Ludwig Weimann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Tech Global LLC
Original Assignee
Life Tech Global LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Tech Global LLC filed Critical Life Tech Global LLC
Priority to CN201880074593.2A priority Critical patent/CN111801093A/zh
Priority to SG11202003505RA priority patent/SG11202003505RA/en
Priority to US16/757,320 priority patent/US20210186860A1/en
Publication of WO2019079402A2 publication Critical patent/WO2019079402A2/fr
Publication of WO2019079402A3 publication Critical patent/WO2019079402A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
    • A61F2013/0296—Apparatus or processes for manufacturing adhesive dressings or bandages for making transdermal patches (chemical processes excluded)
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N5/00—Computing arrangements using knowledge-based models
    • G06N5/02—Knowledge representation; Symbolic representation

Definitions

  • the disclosure relates , to transdermal patches, tablets, capsules, and pills, as well as to various other vehicles for delivery including sublingual and other disintegrating apporaches, each of which can contain a formulation .providing a pharmaceut ical agent such as a drug or a nutraceutical.
  • a pharmaceut ical agent such as a drug or a nutraceutical.
  • the drug can he focus upon medial, and palliative therapies and in certain cases may include one or more cannabinoids.
  • [00O@3 Dermal patches can take the fomi of a monolithic- style patch or a reservoir-style patch (see, US 9.962,340 - US 2017/0071870 of Weimaan, which is hereby incorporated herein in its entirety).
  • Monol thicr style -patch can. take the form of a sandwich, where the face that is exposed to the atmosphere is a backing, where the opposite face is a release liner, and where the filling of the sandwich is a matrix: that includes an adhesive and a pharmaceutical, agent such as a drag or nutraceutical Prior to applying the patch to the skirt a release liner is removed and discarded.
  • the reservoi -can contain a pharmaceutical agent that is -drug or a natraceutical.
  • the -reservoir also contains a liquid carrier and a. gelling agent
  • the reservoir can be defined by a backing and by a permeable membraine, which together assume a "ravioli" conformation.
  • the permeable membrane is optionally coated with an adhesive that mediates binding of the adhesive to the skin. On one side of the adhesive is the permeable membrane, and on the other side is a release iinter. Prior to applying the patch to the skin, a release liner is .removed and discarded.
  • Dermal patches are used to deliver capsaicin for reducin pain.
  • the patch delivers capsaicin.
  • Capsaicin acts on peripheral nociceptors.
  • the patch can be applied for about one hour, where theresult is pain reduction for many weeks (see, Peppin et al (2011) J. Pain Res. 4:385-392), Dermal patches are also used to deliver iorigotine for treating Parkinson's disease, and where the patch provides continuous drug delivery over 24 hours, resulting in plasma pharmacokinetics similar to that with continuous i.v. infusions..
  • Rotigorine acts on dopamine receptors (see, Elshoff et al (2015) Drugs. 75:487-50.1).
  • dermal patches ' can provide estrogen for therapy to postmenopausal women, and to provide ethinyl estradiol and norelgestromin for contraception.
  • the contraceptive patch is used for1 days, and it provides systemic concentrations similar to that with a daily oral contraceptive (see, Jung et al (2013) Drugs. 13:223-233).
  • the present disclosure provides -sublingual tablets, capsules, pills, and strips, as well as: buccal patches and dermal patches. These objects are provided herein as novel and enhanced tablets, capsules, strips, and patches that contain one or more drugs. Also provided are these same novel and enhanced objects,, thai do not: contain one or more drags, for example, as might find use as a placebo.
  • the present disclosure provides a composition capable of use in a buccal patches, sublingual patch, pill, tablet, or a dermal patch, or eyedrop wherein the composition comprises one or more of, an acrylic adhesive with non-functionaiity and an. adhesive with, only QH-functionality, further -comprising one of more of enhancers selected from azone, oleic acid, and din ethylsulfoxide (DMSO) a polyisobutyiene (FIB adhesive) with iaefcserverrs that improve adhesion to skin using acrylic pressure sensitive adhesive mixed in at 1-50%, optionally with a
  • DMSO din ethylsulfoxide
  • FIB adhesive polyisobutyiene
  • CBD eannahidiol
  • THC tetraliy
  • the oil is mixed with EtOB. /water (80/20, vol/vol), optionally -with one or more enhancers, selected . from azone, oleic acid, and limonene; or a THC oil of THC (80-95%) mixed with 1 -20% EtOH or with 1-10% EtOH water (80/20, vol/vol) wherein including greater than 10% of ethaiiol is capable of lowering flux of THC deliver ' as determinable with a reservoir patch.
  • a buccal patch, sublingual pill, sublingual tablet, or sublingual patch comprising one of the above compositions.
  • a dermal patch comprising one of the above compositions
  • a method for applyin the above buccal patch to the buccal mucosa of a human subject, and allowing a cannabinoid to transit from the buccal patch into the buccal mucosa of the human subject.
  • a method for applying the above dermal patch to skin of a human subject, and allowing a cannabinoid to transit from the buccal patch into the skin of the human subject is also provided.
  • ⁇ 00145 What is also embraced is a method for manufacturing the above patch, comprising the steps of combining- THC, a film, an adhesive, and a backing, to generate an uncu patch, further comprising; the uncut patch, to produce a cut patch that is capable of applying to human skin or of applying to human buccal pouch.
  • the present .disclosure provides dermal patches, formulations, demial patches not containing a formulation, and dermal patches -including a formulation.
  • Preferred formulations include one or more eannabmoids.
  • the major carmabinoids from cannabis sativa are eannabidiol (CBD), caiinabiehramene (CBC), c nnabigerol. (CBG), delta-9-ietrahydrocannabmol (delta -9» THC), and eannabinol (CBN) Appendino et. at (2008) J. Nat. Prod. 71:1427-1430).
  • Cannabis can improve neiiropatliic pain of multiple sclerosis, improve appetite and sleep quality in cancer patients, relieve pain in fibromyalgia patients, and serve as an antiemetic for chemotherapy induced nausea and vomiting (see, Health Canada (Feb. 201,3.) Information for Health Care Professionals. Cannabis (Marihuana, Marijuana) and the Cannabinoids (152 pages)). The present disclsoure also provides tetrahydiOcannabinovarin (THCV), which is a propyl analogue of THC, and.
  • THCV tetrahydiOcannabinovarin
  • CBD camiabidivarin .(CBDV), which is a propyl analogue of CBD.
  • Formulations and compositions, that include both THC .and CBD at a given ratio are provided, such as at the ratio of about 95/5, about 90/10, about 80/20, about 70/30, about 60/40, about 50/50, about 40/60 » .about.30/7.0, about 20/80, about 10/90, and about 5/95 (by weight).
  • Administering formulations containing both THC and CBD can have greater influence on reducing pain that formulations containing only THC or only placebo (see, Johnson et al (2010) J. Pain Symptom Management. 39:167-179; Motcuti et al (2004) Anaesthesia. 5944-452).
  • Cannabinoids can. be included in the compositions of the present disclosure.
  • Cannaboids and related compounds further include, for example,
  • monolith patch can be made as follows. Cannabis oil or one or more pure cannabinoids can be combined with permeation enhancer only, combined .with carrier only, or combined with both permeation enhancer and carrier.
  • Carrier can comprise, for example, one or more of oleic acid and dodecylmethyi sulfoxide. Then one or more pure terpenes, or an. essential oil, or combinatio of an es sentia! oi l and one or more pure terpenes, is mixed with the above combination. Then, a polymer such as a -silicone polymer is mixed in.
  • tlie mixture is spread into one or more sheets, cured at room temperature fo several hours or longer. After drying, a foam backing laye is applied, and then the product is. cut into shapes (e.g., squares, rectangles, ovals, round-edged squares or round- edged rectangles, circles) suitable for applying to the skin of a person.
  • shapes e.g., squares, rectangles, ovals, round-edged squares or round- edged rectangles, circles
  • a laminate that can be held in place on the gingiva takes the form of a semipermeable ' outer layer, reservoir having a pharmaceutical, .backing layer, where the backing layer faces the gingiva.
  • Saliva can enter through the semipermeable outer layer, pass, through the reservoir, and then draw medicine into contact with gingiva for absorption in the bloodstream,
  • a pharmaceutical can be freeze dried or can occur as a hydroge! matrix, in the reservoir.
  • the present disclosure provi des a backing layer of one o more polymers, such as, ethyl cellulose, butyl cellulose, hydroxybutyl cellulose, or polyvinylalcoheL
  • amorphous or semi-crystalline excipient matrix can be made from memyleelMose, ethylcellulose, hydrox propyl
  • the present disclosure can exclude one or more of these polymers,
  • a phannaeeitdcal or utraceuScal can be distributed evenly throughout reservoir, or can be distributed at a higher concentration at center • of res.ervior, or can be distributed at a higher concentration at region of reservoir that is closer to the skin when patch is situated and adhering to skin.
  • [003$]Hy ⁇ $rogeis are 3 -dimensional, cross-linked networks of water-soluble polymers.
  • the porous structure of ' hydrogels can be altered by changing the density of crossdmkii g.
  • the degree of crass-linking .can. alter the rate, of loading , a drug; and i t can alter the rate of drug release.
  • the present disclosure can encompass a hydrogel that consists of one of the following polymers or alternatively, that comprises one or more of the following polymers (e.g., as a block
  • ga ma-cye odextrin 8 giueopyranose units.
  • Methylate cyelodextrms can im rove acqueous solubility, dissolution rate, and bioavailability of eamiabinoids.
  • the present disclosure provides a dermal patch (or buccal patch) comprising a dextrin where the dextrin is not compiexed with a pharmaceutical, agent, and a dermal patch (or buccal patch) comprising a dextrin where the dextrin is, in fact compiexed with a pharmaceutical agent.
  • the present disclosure can exclude a fomiuiation thai comprises a cyclodextrin, or that comprises an alpha- cyclodextrin, or that comprises a beta- cyelodextrin, or that comprises a gairima-cycSodextrin.
  • a device that comprises a cyclodextrin, such as an adhesive dermal patch comprising a dextrin or a buccal patch comprising a dextrin.
  • a matrix, carrier, or binder can include, e.g., hydrogel, polyethylene oxide,
  • a&y!eeiiuloses veegums -clays, alginates, PVP, algmic acid, carboxyinethylceilu!ose calcium.
  • what can be excluded is one or more of the above polymers, clays, waxes, hydrogels, starches, and gums.
  • a po yol can be used, for example, as a carrier.
  • Poiyo!s include propylene glycol, and glycerol and the preferred (poly) alkoxy derivatives include poiyaikoxy alcohols, in particular 2-(2-ethoxyelhoxy) ethanol (Transeutol®).
  • Gums suitable for buccal tablets are disclosed, in US 4,829,056, which is incorporated by reference in its entirety.
  • Lozenges and sublingual, pills are provided, and these can comprise: one or more of sodium phosphate, potassium phosphate, guar gum, gum arabic, locust bean gum, xanthan gum, earrageenan, -carob gum, ghatti gum, pectin, rragacanrh gum, acacia gum, manmtoi, sorbitol, lactose, modified lactose, maltitoi, maunitol, magnesium stearate,
  • Matrix can be manufactured by melt-granulation, melt-extrusion, using particulates, granules, bi layers* plasticizers, and the like (see, US2016/0151502 of Wright), Patch can be made with silicone adhesives disposed on a substrate, copolymers, block polymers, tackifymg resins, hot melt coating processes (see, U S2014/034 108 of Fung). Patch ca be made with backings, release liner, pressure sensitive adhesives, silicone gel adhesives (see,
  • Dermal patch, buccal /patch, tablets can be made with exeipient, disiiitegrant, swelling agent. Films, binders, and the like (US2Q1 /0079740 of Salama).
  • Hot-melt extrusion, granules, tablets, transmucosa! patches, transdermal patches, and methods of manuiature are detailed (Crowley et al (2007) Drug Development Industrial Pharmacy. 33:909-926; Repka et al (2007) Drug Development Industrial Pharmacy. 33: 1043-1057).
  • sublingual tablets sublingual pills, and sublingual strips
  • equipment for compressing granules, for applying coatings and lubricants are available (see, US2010/0233257 of Herry).
  • sublingual tablets and buccal tablets formulas involving, e.g., cross-linked carboxymethylceiluiose, lactose, macrocrystalline cellulose, binding liquids, and equipment such as drier, niiXer-granulaior, compressor, are disclosed (see, e.g., US 9,308, 12).
  • Penetration enhancers, fillers, binders, carriers, equipment for molding and solidifying sublingual tablets are disclosed (US ' 9,220,747 of Gould). Each of these patent documents is incorporated herein by reference in its entirety.
  • the present disclosure can encompass films, sheets, layers, membranes, and the like that have a plurality of apertures or pores.
  • the ' apertures or pores have an average diameter of 20nm, 40nm, 50nm, lOOnrn, 200am, 300nm, 40Onm 5 SOOnm, SOOnm, SOOnm, 0.:001mm, 0.002, 0.005mm,: 0.010mm, 0.015mm, 0.020mm, 0.025mm, 0,030mm, 0,040mm, 0.050mm, 0.075mm, 0.10mm, 0,20mm, 0.30mm, 0.40mm. 0.50mm, and the like.
  • the pores can have a diameter range where the range is bracketed b any two of these values .
  • the apertures or pores have a diameter in the range o 20-40nm, 40-60nm, 60- 80nm, 50-lOOnm, lO0-200nm, 200-400nm, 400-600nm, 600-800nin, 800-1 ,000nm, 0.001- 0.002mm, 0.001-0.005mm, 0.005-0.010mm, 0.010-0,020 m 3 0.020-0.040nmi, O.025 ⁇ 0.O5Omm, O,050-O.075mm, 0.075-0.10mm, 0.i0-0.20mm, 0.20mm-0.40mm, 0.25-0.50mm, 0.50-0.75mm, citrate esiers-lriethyl citrate, acetyltriethyl citrate, tributyi citrate, aceiyltributy!
  • citrate citrate, benzyl benzoate, sorbitol, xylito.1, bis(2 ⁇ ethyl)hexyl) adi te, mineral oil, polyhydrie alcohols such as glycerin and sorbitol, glycerol esters such as glycerol, triacetate; fatty acid triglycerides, polyoxyethylene sorbitan, fatty acid esters such as TWEEHS, polyoxyethylene tnonoaikyl ethers such as BRIJ series and MYRJ series, sucrose, moiioesters, lanolin, esters, lanolin ethers. These are available from ' Sigma-ALdricl , St. Louis, MO. In exclusionary embodiments, what can be excluded is any composition, formulation, dermal patch, and methods that '.comprise one or more of these solubili?.er.s or surfactants.
  • compositions, formulations, devices, and methods that comprise one or more surfactants, such as. sorbitan trioleate, sorbitan mono-oleate, sorbitan .rnonolaurate, polyoxyethylene (20) sorbitan rnonolaurate, polyoxyethylene (20) sorbitan menooleate,.
  • surfactants such as. sorbitan trioleate, sorbitan mono-oleate, sorbitan .rnonolaurate, polyoxyethylene (20) sorbitan rnonolaurate, polyoxyethylene (20) sorbitan menooleate,.
  • the present disclosure can exclude .one or more of the above chemicals, and can also exclude a composition, foroiuiations, device, and method
  • the present disclosure can include formulations that contain a buffer with a p a, as measured at room temperature* such as boric acid (pKa 9.2), CHES (pKa 9.5), bicine (pKa 8.3), HEPES (pKa 7.5), MES (pKa 6. ⁇ ), MOPS (pKa 7.2), PIPES (pKa 6.8), Tris (pKa 8.1), imidazole (pKa .6.9), glycine (pKa 2,3), acetate (pKa 4.7).
  • boric acid pKa 9.2
  • CHES pKa 9.5
  • bicine pKa 8.3
  • HEPES pKa 7.5
  • MES pKa 6. ⁇
  • MOPS pKa 6.8
  • Tris pKa 8.1
  • imidazole pKa .6.9
  • glycine pKa 2,3)
  • acetate pKa 4.7
  • the present disclosure can exclude formulations, that include one or more of the above buffers, and can exclude a device that comprises one of these formulations-.
  • the present disclosure provides a .formulation, or provides a component of a formulation,, that has a pH -value,, as measurable at room temperature, of about 3.0, 3.1, 3.2, 3.3, 3.4.
  • the present disclosure can exclude a formulatioa, or can exclude a component of a formulation, that has a pll value, as measurable at room temperature, of about 3.0, 3,1, 3.2, 3.3, 3.4, 3.3, 3.6, 3.7, 3.8, 3.9, 4.0, 4,1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5,1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5,8, 5,9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6,6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8,0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.Q, and the like.
  • the pH of component can. be measured as pure component, that is, prior to combining with other components to generate formulation.
  • the present disclosure encompasses patch-based delivery systems for use in the mouth.
  • regions for drug delivery include sublingual mucosa (area beneath the tongue) and the buccal mucosa .(inner lining ox the cheeks), Buccal adnimistration: of low water-solubility pharmaceuticaJ s can be enhanced by formulating pharmaceutical in combination with a surfactant, or as a complex with hydrophilic cyclodestrins, or by. using a naspsuspenskm
  • Nanopart es can be made by milling, homogenizatlon, or ultrasonieatioii.
  • Buccal dosage forms are inserted into the buccal pouch (see, US 8,735,374 of Zetbe, which is incorporated herein in its entirety).
  • Buccal patch can include an emulsifier that, when exposed to water, results in hydration- induced formation of an eniuisifier. Emulsion, can form spontaneously, that is, whithout much energy supply or without shearing forces, when water contacts the emulsifier. When placed against the gems, saliva drawn into the buccal patch can be the source of water.
  • Self-emulsifying agent enhances the tendency of the formulation to adhere to the mucosal surface, thus promoting absorption of pharmaceuticals such as cannabinoids (see, US 7,709,536 of Dam and US 8,642,080 of Bender, each of which is incorporated ..herein by reference in its entirety).
  • buccal patch can consist of. wo laminates, with an. aqueous solution of an adhesive polymer being east on an impermeable 'backing ' sheer.
  • One type of adhesive film can comprise an alcoholic solution of .hydroxypropyl cellulose and organic acids. This adhesive film stays in place for at least 12 hours, even in the presence of fluids.
  • Adhesive patches can he made by solvent casting or by direct milling. In solvent castiiig, all excipienis and the drug are- dispersed in an organic solvent and coated on a sheet of release liner.
  • buccal film can be made by solvent casting method and by hot melt extrusion method.
  • Solvent casting involves dissolvin water-soluble polymers to form viscous solution. Exciparias are dissolved into solvent t give clear viscous solution. Then, both solutions are mixed (solution of water-soluble polymers; exeipient solution) and then cast as a film, and then, allowed to dry.
  • the drug or combination of drugs is in a dry state, and it is filled, in a hopper, mixed, heated, and then extruded in a molten, state. The molten niass that is formed is. used to cast film (Madhavi et a! (2013) Buccal film drug delivery system— an innovative and emerging technology. J - Mol Pharm. Org. Processing Res. Vol. 1 , Issue 3 (6 pages))..
  • mueoadhesive patches can be made by dissolving , polymers in a solvent to produce a viscous solution.
  • the polymers can be hydroxypropylniethyl . cellulose (HPMC) E5LV and Carhopol® 940P.
  • Polyethylene glycol 1000 can he included as a plasticizer.
  • The. solvent can be ethanol: chloroform (50;5G).
  • drug can be dispersed in it.
  • the solution can be poured into molds for casting and dried, for 24 hours. After drying, patches can be cut, fo example* at 2 cm x 2 cm.
  • Each of the patches can contain, for eax !e. 2mg drug, 20nog BPMC, 0.4mg Carbopol, and 17mg PEG100 (wt voi) (see, Priya et al (201 1) J. Pharrm Res. 3:56-65),
  • Instron® 3366-2716015, Germany see, Priya et al (2011) J. Pharm. Res. 3:56-65.
  • Franz diffusion cell can measure drug release and permeation, with in. vitro teste (Cavaiiari et al (2013) Eut. J. Ph rm. Biopharm, 83:405-414; Technical Brief 009,. volume 10. Development and validation of in vitro release testing methods for semisolid formulations (Particle Sciences, Bethlehem, PA).
  • Patch thickness- can be measured wit a screw guage, where thickness can be measured at various different spots on the patch.
  • To measure surface pH. patch can be allowed to swell for 2hours on the surface of an agar plate (2% w/v), and the pH the measured with pH paper.
  • Swelling can be measured by taking the weight each hour for six hours, after placing patch o an agar plate (see, Verma et al (2014) Effect of novel mucoadhesive buccal patches of caivediol on isopeiialme-indueed tachycardia. J. Adv.. Pharm. Techno I. Res. 5:96-103).
  • the present disclosure provides emulsions, emulsifying agents, self-emulsifying agents, creams, and lotions. Th following provides examples of self-emulsifyin agents.
  • Self-emulsifying agents include glycerol monostearate, glycerol nionooleate, and
  • Gremophor RH40® Cremopho RH40® is polyoxyl 40 liydrogenated castor oil. Cremophor EL® is polyoxyl 35 castor oil. These chemicals can be obtained from BASF Aktiengesel!schaft, Ludwigshafen, Germany, hi one aspect, the present disclosure can include formulations that comprise a seif-eniulsiiying agent. In anothe aspect, the present disclosure can exclude formulations, and can exclude devices, that comprise a self-emulsifying agent.
  • [0 ⁇ 67J SqhibiJizer SL-I l is a self-ex ulsiiying agent that provides a nanoemulsion- suitable for eontaining-a hydrophobic drug (NOF America Corp., Irvine, CA ⁇ . Emulsion with, particle size under Silnan pasters can. ' be made- y these: steps; (1) Dissolve drug in a .suitable solvent* such as ethanol; (2) Add .the drug solution prepared in (1) to Soluhi!izer SL-11 > thoroughly mix to completely dissolve the contents.; (3) The drug/SL-l 1 solution with solvent is made; (4)
  • .self-emulsifying agents can be made with polyglycolyzed glycerides (PGG) w th varying fatty acid and polyethylene glycol (PEG) chai lengths, where these produce the self-emulsification of oil in water.
  • PEG polyglycolyzed glycerides
  • PEG polyethylene glycol
  • the quality of the resulting emulsions depends on the oil and emii!sifter pair seleetedm and on die concentration .ofP ' GG- as the emulsifier.
  • One suitable oil is an oil with a medium-chain triglycerides (caprylic acid and capric acid; Neobee MS ⁇ ).
  • Another suitable oil is peanut oil.
  • PGG was found to he a workable emaisifiers fGr use in self-emulsifying drug delivery systems (SEDDS) (Sha et ai. (1994) Int. J. Pharmaceutics. 106:15-23).
  • Gelucire® 44/14 was ground into a powder by cryogenic grinding to produce solid oral dosage forms and resulting in formulations made of Gelucire® 44/14 and ketoprofeh (90/TO), Cryogenic grinding produced .Gelucire €> 44/14 in a powder form >: where this process did not change its physical properties, emuisiftcation capacities and dissolution performanees of the form ulation tested.
  • Biophaim. 109:113-1:21 described emulsifying properties of SEDDS composed of long chai lipids (LC ⁇ S£TJDS),.medium chain lipids (MC-SEDDS), short chain lipids (SC-SEDDS ) and no lipids (NL-SEDDS).
  • the drug, enpxaparin was incorporated via hydrophobic; ion pairing in the chosen SEDDS.
  • the average droplet size of chosen LC-SEDDS, MC-SEDDS and NL-SBDDS ranged between 30 and 40nm.
  • MC-SEEDS containing 30% Capte 8000, 30% Capmul MC-M, 30% Crempphor EL and 10% propylene glycol and l L-SEDDS containing 31.5% Labrafil 1944, 22.5% Capmul ; PG-8, 9% propylene: glycol, 27 Cremophor EL and 10% DMSO exhibited 2- fold highe mucus diffusion than LC-SEDDS.
  • Both MC-SEDDS and NL-SEDDS showed sustained in vitro enoxapaiin - release.
  • -Orally administrated MC-SEDDS and NL-SEDDS yielded an -absolute enoxaparin bioavailability of 2.02% and 2.25%, respectively.
  • emulsifying agent can be characterized by Hydrophilie Lipophie Balance (HLB).
  • HLB system is numbered 1 to.20.
  • HLB values of 3 to 6 are- lipophili and these form water-in-oil emulsions (see, Vadlamudi, Hyndavi, and Tejeswari (2014) Current Drug Discovery Technologies. 11:169-180).
  • HLB values of 8 to 18 are hydrophilie and these: form oil-in-water emulsions (see, Grimberg, b .agel, and Aitken (1995) Environ. Sci. TechnoL 29:1480-1487).
  • the present disclosure provides permeation enhancers, for example, for use with a dermal patch or for a buccal patch.
  • Phosphatidylcholine Polyoxyethylene, Polysorbate . 80, Sodium EDTA, -Sodium glycocholate, Sodium giycodeoxycholate. Sodiu la iryl sulfate, Sodium salicylate. Sodium tauroehoiate, Sodium taurodeoxycholate, Sulfoxides, and Alky! glycosides (see, Shojaei et al (June 2001) Systemic drag delivery via the buccal mucosal route. Pharmaceutical Technology, Pages 70-81).
  • Other enhancers of the present disclosure are 1-octanol. 2-eihylhexanol, i-nonanol, I- decanol, and so on .
  • Pert «atipri enhancers of the present disclosure can be a biphasic composition, having a lipid phase and a water phase.
  • Lipid phase can be prepared by mixing isopropyl pa.imita.te and lecithin.
  • Water phase can he mixture of water and a surfactan Surfactant can be Pluronic®, Pemulen®. oveon®, or Carbopol®.
  • Carbopol hpmopplymers are acrylic acid erosslinked with ally! sucrose or .ally! .pentaerythritol.
  • Carbopol copolymer are acrylic acid and C10-C30 alky I acrylate erosstmked with ally! ..pentaerymritoi (Lubrizol, Inc. product sheet).
  • Noveon® Polycarbophii, L ! SP is a high molecular weight. acrylic acid polymer crossHnked with divinyl glycol (Lubrizol, Inc. product sheet).
  • Pluro.nie ⁇ polymers are block copolymers based on ethylene oxide and propylene oxide.
  • the present disclosure can exclude any formulation, composition, device, method, and such, that comprise one or more the molecules found in Piivronic®, Pemulen®, Noveon®, and Carbopol'®,
  • PLOGel is "Plutonic Lecithin Organogel' 1 (Fhaimedica Enterprise, Selangor, Malaysia). PLOGel takes the form of an aqueous phase (240rnL poloxamer 407, potassium sorbate, water) and organic phase (60mL lecithin, isopropyl palmitate, sorbic acid).
  • the present disclosure can exclude any formidaiion, composition, device, method, and such, that comprise one or more of PLOGel, poloxamer 407, potassium sorbate, isopropyt palmitate, sorbic acid, lecithin, and .the like.
  • the present disclosure can exclude any formulation, compositi on, device, method, and such, that encompasses one of the above polymers, polymer compounds, and crossMnked polymer compositions.
  • Bioadhesive material serves a matrix for retaining pharmaceutical agents, until patch is applied to the skin or to a mucosal surface of the consumer.
  • Bioadhesive materials include, hydroxypropyl cellulose, earbopol, polyvinyl pyrrolidone), sodium
  • the present disclosure provides . formulations, emulsions, arid the like, as well as buccal patches and dermal patches, where the formulation, ⁇ emulsion, buccal patch, and dermal patch, contains one or more of vitamin Bi, vitamin Ds, vitamin B12, or vitamin C, optionally in combmation with one or more cannabinoids. Also, t e. formulation, emulsion, buccal patch, and dermal patch, can contain sildenafil.
  • compositions, formulation, dermal patch, methods of use, methods of manufacture that comprise one or more of the following capsaicin,
  • the present disclosure can also exclude one or more of, 23-lauryi -ether, Aprotinin, Azone, Benzalkord urn chloride, Cetylpyndinium chloride, Cetyltrimethylammoniom bromide, Cyclodextrin, Bextrars sulfate, Why acid, Why
  • a formulation, composition, device, or method that comprises pre-gelatinized starch, gelatinized starch, gelatinized corn starch, glyeogelatin, alpha-toeopherol, glyeogelatin Jiernp oil, THC, CBD, gum acacia, sorbitol, xyiitol, soy lecithin, a complex of two different gels (one with net negative charge and the other with net positive charge), and a compositions that comprise a solvent with a cosolvent.
  • a system of solvent/cosolvent can be ethaiiol •(suiteypropylene glycol, (cosol vent).
  • Solvents can be anhydrous alcohol, ethaiiol, propanol, o isopropanoi.
  • Cosolvent can be propylene glycol or PEG.
  • Ratio of sol ent/eosGlyeat can be about 5/95, about 10/90, about 15/85, about 20/80, about 25/75, about 30/70, about 35/65, about 40/60, about 45/55, about 50/50, about 55/45, about 60/40 about 65/35, about 70/30, about 75/25, about 80/20, about 85/15, about 90/10, about. 5/5, and the like.
  • the present disclosure can exclude solvent/'cosolvetvi compositions where the ratio is, 5/95, about 1.0/90, about 15/85, about.20/80, about 25/75, about 30/70, about 35/65, about 40/60, about 45/55, about 50/50, about 55/45, about 60/40, about 65/35, about 70/30, about 75/25, about 80/20, about 85/15, about 90/10, about 95/5, and the like.
  • a formulation with an eihanol content by weight of about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%;, about 95%.
  • a fomiulation with an ethaiiol content by weighty that encompasses about 5%, about 10%. about 15%,.
  • a formulation with an ethanoi content, by weight that encompasses (range that equals or range that includes) a range that is .5-1.0%, 10-15%, 15-20%, 2.0-25%, 25-3.0%, 30- 35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100%.
  • the present disclosure can provide a lomiiilation that comprises ethanol and propylene glycol (or glycerol monostearate, or glycerol monooleate, or monoglyceride, or dig] yceride, or tiiglycemie. or PEG,, or phospholipid, or surfactant), and where the ratio .(weight weight basis) is about 5/95, 10/90, 15/85, 20/80, 25/75, 30/70, 35/65. 40/60, 45/55, 50/50, 55/45, 60/40, 65/35, 70/30, 75/25, 80/20, 85/15.
  • a formulation that comprises.- ethanol and propylene glycol (or glycerol monostearate, or glycerol rnonooleate, or monoglyceride, or diglyceri.de, or triglyceride, or PEG, or
  • phospholipid, or surfactant where the ratio (weight weight basis) is about 5/95, 10/90, 15/85, 20/80, 25/75, 30/70, 35/65,.40/60, 45/55, 50/50, 55/45, 60/40, 65/35, 70/30, 75/25, 80 20, 85/15, 90/10, or 95/5.
  • Formulations with specific concentrations, on a weight basis, of propylene glycol or of any other coiBpound can be excluded. What can be excluded are formulati ons containing about 0.1%, of about 0:2%, of about 0.4%, of about 0.6%, of about 0.8%, of about 1.0%.
  • propylene glycol polyethylene glycol (PEG), polyalkyiene glycol, ethanol, emulsion (e.g., oil droplets in water, water droplets in oil, liposome suspension), colloid, solvent, penetration enhancer, stabilizing agent, sohibilizmg agent (e.g., surfactant, detergent), gelling agent (either in dry state or in hydrated state), hydrogel (either in dry state or in hydrate state), adhesive, or any other compound,' can be excluded,
  • PEG polyethylene glycol
  • polyalkyiene glycol ethanol
  • emulsion e.g., oil droplets in water, water droplets in oil, liposome suspension
  • colloid solvent, penetration enhancer, stabilizing agent, sohibilizmg agent (e.g., surfactant, detergent), gelling agent (either in dry state or in hydrated state), hydrogel (either in dry state or in hydrate state), adhesive, or any other compound,' can be excluded,
  • sohibilizmg agent e.g.
  • formulations that encompass (range that equals or range that includes) the range of 0-0.1%, 0-5%, 0-10%, 0-20%, .0-30%, 0-40%, 0-50%, 5-10%, 5-15%, 5-20%, 5-40%, 5-50%, 1.0-20%, 10-30%, 10-40%, 10-50%, J 0-60%, 10-70%, 20-30%, 20-40%, 20-50%, 20-60%, .20-70%, 20-80%, 30-40%, .30-50%, 30-60%, 30-70%, 30-80%, 40-50%, 40- .60%, 40-70%, 40-80%, 40-90%, 50-60%, 50-70%, 50-80%, 50-90%, 60-70%, 60-80%, 60-90%, 60-100%, 70-80%, 70-85%, 70-90%, 70-95%,.70-100%, 80-85%, 80-90%, 80-95%, 80-100%, 85-90%, 85-90%, 85-90%, 85-90%,
  • the present disclosure can include (encompass, comprise) a formulation, composition, device, or method that comprises one or more of the above chemicals, at any of the recited '"about” values, and at any of the recited ranges.
  • a compos tion thai comprises one or more of the following compounds, and can also exclude a device that co rises- one or more of the following compounds. What can be excluded is a compound that is, buptenorphine, clonidine, estradiol, fentahyl, granisetron, methyiphenidate, nitroglyeerm.
  • a mammalian hormone a synthetic analogue of a mammalian hormone,, a .chemically odified mammalian hormone, lidocaine, estrogen, salieyelic acid, a: contraceptive, rivastigrnine, rotogotine, mlobnterof, adrenergic agonist, cholinesierase inhibitor, dopamine receptor agonist, oxybutynin, bupropion, varemoiine, nicotine, antidepressant, smoking cessation drug, eholinsterase inhibitor, methyiphe.nidate, b prenorpliine, opioid analgesic agent, sumatriptan, antiviral drug, anti-retroviras drug, mammalian steroid, chemical analogue of mammalian steroid, drug .for attention-deficit hyperactivity
  • the present disclosure can exclude a reservoir-type device where backing does not directly contact reservoir; or where reservoir does not directly contact faydrophilip porous membrane; or where hydrop !ic porous membrane does not directly contact a release liner; or where reservoir does not contain all of: (! ) a liquid carrier, (2) a gelling agent, and (3) CBD. Also, what can be excluded is. a reservoir-type device that does not comprise all of the above.
  • an adhesive polymer or a device comprising an adhesive; polymer, where the adhesive polymer reacts with amines.
  • an adhesi ve polymer or a device comprising an .adhesive polymer, where the adhesive polymer has any free ⁇ ⁇ hydroxy, groups, where the adhesive polymer has over 1 free hydroxy!
  • any polymer consists of a large number of atoms, for example, about five thousand atoms.
  • a preparation, or a device comprising. preparation where the preparation has under 1% gelling agent, under 2%, under 3%, under 4%. under 5%, under 6%, under 7%. under 8%, under 9%, under 10%, under 12%, under 14%, or under 16%, of gelling agent,
  • a preparation, or a device comprising a preparation where: the preparation lias over 1% penetration enhancer, over 2%, over 3%, over 4%, over 5%, over 6%, over 7%, over 8%, over 9%, over 10%, over 12%, over 14%, or over 16%, of penetration enhancer.
  • a preparation, or a device comprising a preparation where the preparation has under 1% penetration enhancer, under 2%, ; under 3%, under 4%, under 5%, under 6%, under 7%, under 8%, under 9%, ⁇ under- 10%, under 12%, under 14%, or under 16%, of penetration enhancer.
  • CBD or THC, or combined weight of CBD and THC
  • a preparation a composition, a device comprising a preparatioh, a device comprising a composition, where said preparation or composition has a CBD (or THC, or combined weight of CBD and THC) content by weight that is .greater than 5%, greater than 6%, igreater than 7%, greater than 8%, greater than 1.0%, greater tha 12%, greater than.
  • CBD or THC, or combined weight of CBD and THC
  • compositions can refer- to, for example, matrix of a skin adhesive, or to fluid in hydrephilic porous membrane, and so on.
  • present disclosure can comprise one or mor of the above compositions, as. set forth by "under” parameters or n greater than” parameters.
  • -what can be -excluded is any device that, does not include an occlusive system polymer film, that does not include, a- polyethylene occlusive polymer film, that does not include a PET occlusive polymer film, that does not include an ' occlusive polymer film made of both polyethylene and PET. Also, what can be excluded is a device that has .an overlay patch, and a device that does not comprise an overlay patch.
  • polar Organic-liquid can comprise, or -can exclude, one or more of methanol, ethanol, propanol, isopropanol. butanol, pentaaol, acetic acid, propionic acid, butyric acid, valeric acid, eaproic -acid, caprylic acid, caprie acid, iaurie acid, myristic acid palmitic acid, stearic acid, palmitoleic acid, oleic acid, lino-leic acid, linoienic acid, linear alkanes of 5, 6, 7, 8, % 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or more carbons, branched chain alkanes with a backbone of 5, 6, 7, 8, 9, 10, I I, 12, 3, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or more carbons, linear alkenes (olefins) of 5, , 7, 8, 9, 10, 1 i, 12,
  • the present disclosure can comprise one or more of the above polar organic liquids.
  • the present disclosure can exclude a composition, device, .method, that comprises an . essential oil, a plant oil, a vegetable oil, or a fish oil. Also, the present disclosure can exclude a composition, device, method, that comprises one or more terpenes. What can be excluded is a composition, device, method, that comprises one or more of peppermint oil, .orange oil, lemon oil, -.cannabis oil, hemp oil, and so on.
  • compositions, device, o method that comprises one or more of aipha-bisaboiol, bomeol, alpha-caryophyUene, beta- Qaryophylleae, ele ene (alpha, beta, gamma, or delta), lin onene, camphene, camphor, deita-3- carene, caryophyliene oxide, alpha-eedreen, eltral, eucalyptol, beta-e ' udesmo ' l, eudes.m-7(i i)-eri- 4-qI, famesene, fenchol, aiplia-gnaiene, gerariioi, guaiol, germaniacrene B, guaia ⁇ l(10 l 1-diene, humuiene, alplia-huniulene, isoborneol, linalool, .menthol, ni
  • alpha-pinene be a-pinene, pulegone, sabinene, alpha- erpinei e, alpha-terpineol, terpinolene.
  • terpineol thymol, trans-2- pinanol, selina-3,7(l l)-diene, or valencene.
  • a formulation, composition, device, lozenges, or subfingoa! pill that comprises one or more of sodium phosphate, potassium phosphate, guar gum, gum ara ic, locust bean gum, xanthaa gum, earrageenan, carob gum, ghatti gum, pectin, tragacanth gum, acacia gum, mannitol, sorbitol, lactose, modified lactose, maltitoL mannitol, magnesium stearate, hydroxypropylmethyicell lose film, non-crystallizirig sugar, or non- crystallizing sugar alcohol.
  • any formulation, composition, device, method, and such that comprises menthol and isopropyi myristated in one of the following ratios (weight/weight): 200/10, 180/10, 160/10, 140/10, 120/10, 100/10, 90/10, 80/10, 70/10, 60/1:0, 50/10, 40/10, 30/10, 20/10, 15/10, 10/10, and so on, or one of the fallowing -ratios; 10/10, 10/15, 10/20, 10/30, 10/40, 10/50, 10/60, 10/70, 10/80, 10/90, 10/100, 10/120, 10/140, 10/160, 10/180, 10/200, and so on.
  • thai comprises menthol and isopropyi myristated in one of the following ratios (weight/weight): about .200/10, about 180/10, about 160/10, about 140/10, about 120/10, about 100 10, about 90/10, about 80/10, about 70/10, about 60/10, about 50/10, about 40/10, 30/10, 20/10, 15/10, 10/10, and so on, or one of the following ratios: about 10/10, .
  • compositions defined by a range of any of the above two ratio values.
  • Aerosols and dry powder formulations fo ' inhaling are available. See, Mitchell, Nagel, Wiersema, and Doyle (2003) A APS Phar SciTedi. 4(4) Article 54 (9 pages); Asai et al (2016) Pharm. Res. 33:487-497; opsch et al (2017) Int J. Phara 529:589-596; Fishier . and Sznttman (2017) Inhalation, 11 :21-25.
  • Vaporizers are available, for example, from Storz and Bickel (Tuttlmgen, Germany), . Arizer Tech (Waterloo, Canada), Grganicex (Las Vegas, NV), and Elemental Technologies (Seattle, WA).
  • Sublingual pill, formulation was developed and tested for the active ingredients, cannabidiol and sildenafil.
  • the formulation of the pill was: disintegrating agent (9 grams); m crocrysialline cellulose (24 grams); saccharin sodium (0.75 grams); Mannitol (100 grams); magnesium stearate (1.5 grams).
  • Active ingredients 15 ' grams (CBD, Sildenafil). Total (150.5 grams).
  • Pill formulation was developed to naeet the acceptable performance criteria such as: Hardness, Friability and Disintegration; Hardness (greater than 4 kg/crn2); Friability (less than 2%); Disintegration (less than 100 sec). Sublingual pills were made using a manual pill, press.
  • Disintegrating agent Pharma Burst 500 f om SPI Pharma
  • ⁇ mi-croerystalline cellulose Avicei 102 from F C BioPolymer
  • saccharin sodium Spectrum Chemical MFC • Corp.
  • marmitol from RPI Research Products Memationaf
  • magnesium Stearate Spectrum Chemical MFG. Corp,
  • Sildenafil and cannabinoids are available from, for example, Sigma- Aldrich, St. Louis, MO, For testing pills and tablets, friability, hardness, dissolution, and disintegration can be assessed by equipment from Copley Scientific, Ltd., Nottingham ; UK.
  • Friabiity Tester Series FR FRIOOO, FK200Q, Friabimat SA 0Q
  • dismtegraiion tester DTGiOOO, DTG20OO, TG40OO
  • dissolution apparatus basic, paddle, paddle ever disk, cylinder, and vertical diffusion eel! (Franz cell)
  • Friability is the tendency for a tablet to chip, crumble, or break under compression.
  • FIB adhesive with tackifiers that ' improve adhesion to skin using acrylic pressure sensitive adhesive mixed in at 1-50% ' , Also use of cycloaliphatie hydrocarbon resins such as Escorez 5300 ⁇ resins from Exxon Mobil.
  • the disclosure provides : a graph showing peel strength from skin,
  • the disclosure provides a graph showing transdermal flux.
  • hemp oil with CBD of high concentration 80-95% containing different ferpenes improves transdermal delivery of CBD.
  • the disclosure provides a graph of transdermal flux from matrix with crystalline CBD vs.. matrix wit hemp oil of 86% CBD.
  • CBD and THC Delivery of CBD and THC from semisolid Hydrogels saturated with CBD and THC oils of high, concentration of CBD and THC 80-95%. Oils are saturated in mix with EtOH /water in ratio 80/20 also with enhancers Azon, oleic acid and vase.
  • the disclosure provides a graph of transdermal flux.
  • THC oils of high concentration of THC 80-95%) mixed, with 1-20% EtOH or with EtOH/water 80/20 (1-10%) in reservoir patch delivering high transdermal doses of THC. Addition of more than 10% of ethanol lowers the flux.
  • the ⁇ disclosure provides a graph of transdermal flux.
  • CBD/THC ratio 1/1 m patch produces 2/ 1 transdermal :dose ratio.
  • the disclosure provides a graph of transdermal flux.
  • the disclosure provides Melatonin Patch, Lidoeatne Patch, Menthol, Camphor, Salicylic Acid Patch, Hang Over patch with Dihydromyiicetin.
  • Vitamin Bj patch Vitamin D3 paich, Vitamin B] 2 patch, Vitamin € patch, Sildenafil sublingual pill. Sildenafil fast dissolving strip. Sildenafil buccal patch, Cannabinol sublingual pill, Cannabinol fast dissolving strip, Cannabis ⁇ ! buccal patch, and the like.
  • the present invention is not to be limited by compositions, reagents, methods, diagnostics, laboratory data, and the like, of the- present disclosure. Also, the present invention is not be limited by any preferred embodiments that are disclosed herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • General Business, Economics & Management (AREA)
  • Business, Economics & Management (AREA)
  • Inorganic Chemistry (AREA)
  • Primary Health Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • Manufacturing & Machinery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des complexes pour une utilisation souhaitée en tant que groupes chimiques qui améliorent l'administration de fractions à partir d'un dispositif buccal ou à partir d'un timbre transdermique, le CBD améliorant de façon inattendue la transmission et la disponibilité d'agents actifs.
PCT/US2018/056224 2017-10-17 2018-10-17 Systèmes d'administration améliorés pour des fractions comprenant des combinaisons améliorées de cbd, formulations et chimères Ceased WO2019079402A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201880074593.2A CN111801093A (zh) 2017-10-17 2018-10-17 用于包括cbd增强的组合物、制剂和嵌合体的部分的改善的递送系统
SG11202003505RA SG11202003505RA (en) 2017-10-17 2018-10-17 Improved delivery systems for moieties including cbd enhanced combinations, formulations and chimeras
US16/757,320 US20210186860A1 (en) 2017-10-17 2018-10-17 Improved Delivery Systems for Moieties Including CBD Enhanced Combinations, Formulations and Chimeras

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762573609P 2017-10-17 2017-10-17
US62/573,609 2017-10-17

Publications (2)

Publication Number Publication Date
WO2019079402A2 true WO2019079402A2 (fr) 2019-04-25
WO2019079402A3 WO2019079402A3 (fr) 2019-05-31

Family

ID=66097318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/056224 Ceased WO2019079402A2 (fr) 2017-10-17 2018-10-17 Systèmes d'administration améliorés pour des fractions comprenant des combinaisons améliorées de cbd, formulations et chimères

Country Status (4)

Country Link
US (2) US20190110981A1 (fr)
CN (1) CN111801093A (fr)
SG (1) SG11202003505RA (fr)
WO (1) WO2019079402A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022118303A1 (fr) * 2020-12-03 2022-06-09 Pike Therapeutics, Inc. Formulations pharmaceutiques transdermiques pour le traitement du cancer

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179340B2 (en) * 2017-12-29 2021-11-23 TGC Network LLC Cannabidiol dosage form
BR112020014252A2 (pt) * 2018-01-12 2020-12-01 Nutrae, LLC formulações de canabinóides encapsuladas para distribuição transdérmica
CN112752556A (zh) * 2018-04-27 2021-05-04 雷米生物科学公司 新的医疗装置、递送运载体及其制造
US11235013B2 (en) * 2018-09-04 2022-02-01 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US11229610B2 (en) 2018-09-04 2022-01-25 Babak Ghalili Cannabinoid and menthol gel compositions, patches and methods
US11185526B2 (en) * 2018-09-04 2021-11-30 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US11147775B2 (en) * 2018-09-04 2021-10-19 Babak Ghalili Cannabinoid and menthol gel compositions, patches and methods
US12472103B2 (en) * 2018-11-21 2025-11-18 Bocannaveda, Llc Nano-emulsified cannabinoid or oils in athletic tape and other products
US20220339119A1 (en) * 2019-04-03 2022-10-27 Ely Nigel Stratemeyer-Trinczek Transdermal medicament
KR20250093431A (ko) * 2019-06-11 2025-06-24 어드밴스 파머슈티컬, 아이엔씨. 초과산화물 디스뮤타제 가용성 섬유 조성물
JP7653925B2 (ja) * 2019-06-28 2025-03-31 パスポート テクノロジーズ、インコーポレイテッド 経皮薬物送達パッチ、薬物送達系、および薬物送達方法
KR102915629B1 (ko) 2019-06-28 2026-01-21 패스포트 테크놀로지스, 인크. 필라멘트 디바이스로의 에너지 전달을 제어하기 위한 방법 및 시스템
KR20220054290A (ko) * 2019-06-28 2022-05-02 패스포트 테크놀로지스, 인크. 형성된 통로를 통한 영구적 전달 패치
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
EP4037663A1 (fr) 2019-10-03 2022-08-10 Starton Therapeutics, Inc. Administration transdermique de dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CN114555068A (zh) 2019-10-14 2022-05-27 长矛治疗股份有限公司1219014 B.C.有限公司 大麻二酚的透皮给药
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US11622944B2 (en) 2020-01-31 2023-04-11 Babak Ghalili Stabilized menthol and other volatile compound compositions and methods
US11839592B2 (en) 2020-02-11 2023-12-12 Babak Ghalili Cannabinoid and menthol transdermal delivery systems and methods
WO2021177940A1 (fr) * 2020-03-03 2021-09-10 Babak Ghalili Compositions à base de gel de menthol et de cannabinoïdes, timbres et procédés
WO2021255252A1 (fr) * 2020-06-19 2021-12-23 Cannovex Bv Formulation comprenant des cannabinoïdes
US12109381B2 (en) 2020-08-26 2024-10-08 Babak Ghalili Cannabinoid and menthol transdermal delivery systems and methods
CN114588131B (zh) * 2020-12-03 2024-03-08 汉义生物科技（北京）有限公司 一种大麻素的微针制剂及其制备方法和应用
CN113384558A (zh) * 2021-02-01 2021-09-14 深圳普洛美康材料有限公司 一种递送大麻活性物质的透皮贴剂
US12029720B2 (en) 2021-04-29 2024-07-09 Tilray Brands, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
JP2024521140A (ja) * 2021-05-25 2024-05-28 ロンシー メディカ （ハイナン） カンパニー リミテッド 鎮痛パッチ
AU2021107253A4 (en) * 2021-08-24 2021-12-09 Cymra Life Sciences Limited A composition and uses thereof
WO2024184460A1 (fr) * 2023-03-07 2024-09-12 Lts Lohmann Therapie-Systeme Ag Système d'administration de film avec perforations
CN116832015B (zh) * 2023-08-21 2025-08-26 力品药业(厦门)股份有限公司 一种经口腔黏膜给药的阿戈美拉汀膜剂及其制备方法
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
WO2026052569A1 (fr) 2024-09-03 2026-03-12 Ecole Polytechnique Federale De Lausanne (Epfl) Patch sublingual
CN121081724A (zh) * 2025-10-21 2025-12-09 广东云曌医疗科技有限公司 一种具有大麻二酚的水凝胶伤口贴和制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328992B1 (en) * 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US20060270625A1 (en) * 2005-05-13 2006-11-30 Eastern Virginia Medical School Nutraceuticals for the treatment of neuropathy
WO2008024408A2 (fr) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation
AU2007295179B2 (en) * 2006-09-15 2013-05-30 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
CA2760460C (fr) * 2009-04-28 2019-04-02 Alltranz Inc. Formulations transdermiques de cannabidiol renfermant un agent d'amelioration de la penetration et methodes d'utilisation desdites formulations
CA2772634C (fr) * 2009-08-31 2017-11-21 Alltranz Inc. Utilisation de promedicaments de cannabidiol pour administration topique et transdermique avec des micro-aiguilles
US9186386B2 (en) * 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022118303A1 (fr) * 2020-12-03 2022-06-09 Pike Therapeutics, Inc. Formulations pharmaceutiques transdermiques pour le traitement du cancer

Also Published As

Publication number Publication date
SG11202003505RA (en) 2020-07-29
CN111801093A (zh) 2020-10-20
US20210186860A1 (en) 2021-06-24
WO2019079402A3 (fr) 2019-05-31
US20190110981A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
US20210186860A1 (en) Improved Delivery Systems for Moieties Including CBD Enhanced Combinations, Formulations and Chimeras
US10799545B2 (en) Transdermal delivery of cannabidiol with other active moieties including cannabinoids
US20210228497A1 (en) New Medical Devices, Delivery Vehicles and Manufacturing Thereof
US20240075182A1 (en) Enhanced dermal patch for treating menstrual pain
US11285117B2 (en) Device and method for the transdermal delivery of cannabidiol
CN102821791B (zh) 透皮递送贴剂
DE69430917T2 (de) 3-l-MENTHOXY-PROPANE-1, 2-DIOL ALS LÖSUNGSVERMITTLER UND EXTERNE ZUBEREITUNG, DIE DIESEN ENTHÄLT
US20070207192A1 (en) Adhesive bioerodible transmucosal drug delivery system
MXPA04011808A (es) Liberacion transmucosica de canabinoides.
TW201200134A (en) Transdermal testosterone device and delivery
US10821084B2 (en) Dihydromyricetin compositions
EP1642579B1 (fr) Mouche adhèsive contenant du phentanyle pour la muqueuse de la cavité orale
CZ307857B6 (cs) Transdermální náplast pro podávání fentanylu nebo jeho analogu
KR102686709B1 (ko) 경구용 박막
JPWO2009031318A1 (ja) 鎮痛・抗炎症剤含有外用剤
JP2001527581A (ja) メントの経皮投与
JPWO2010103843A1 (ja) 鎮痛・抗炎症剤含有外用剤
CN105939729A (zh) 皮肤渗透促进组合物、经皮给药制剂及贴附制剂
JP2010059058A (ja) 鎮痛・抗炎症剤含有外用剤
JP2009280509A (ja) 鎮痛・抗炎症剤含有外用剤
KR20060123610A (ko) 구강에서 사용하기 위한 플랫 시스템
US20240074988A1 (en) Devices and methods for the transdermal delivery of psilocybin
HK40129830A (zh) 用於透皮施用石杉硷甲的透皮治疗系统
CN120583943A (zh) 用于透皮施用石杉碱甲的透皮治疗系统
WO2019126166A1 (fr) Compositions pharmaceutiques transdermiques à irritation cutanée réduite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18869415

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18869415

Country of ref document: EP

Kind code of ref document: A2